Aadi Bioscience, Inc. announced that the Board removed Dr. Hehenberger as a member of the Audit Committee, and appointed Caley Castelein, M.D., a member of the Board who meets all audit committee independence and other eligibility requirements identified in Nasdaq Listing Rule 5605(c)(2)(A), to serve as a member of the Audit Committee, such that the Audit Committee consists of Emma Reeve, as chair, Richard Maroun and Caley Castelein, M.D. Dr. Castelein previously served as a member of the Audit Committee from March 2017 to September 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.065 USD | +2.23% | +17.23% | +1.56% |
03-13 | Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
03-13 | Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.56% | 49.6M | |
-3.79% | 87.06B | |
+1.97% | 40.25B | |
-16.88% | 31.09B | |
+52.66% | 24.74B | |
-13.99% | 15.91B | |
-9.12% | 11.96B | |
-15.50% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- AADI Stock
- News Aadi Bioscience, Inc.
- Aadi Bioscience, Inc. Announces Management Changes